| P50 | author | Peter W. Gething | Q30508504 |
| | Patrick Michael Brock | Q52884038 |
| | Thomas S Churcher | Q54802124 |
| | Michael Delves | Q56347973 |
| | Azra Ghani | Q60550218 |
| P2093 | author name string | D Leroy | |
| | R E Sinden | |
| | L M Upton | |
| | A M Blagborough | |
| | K A Sala | |
| P2860 | cites work | A new world malaria map: Plasmodium falciparum endemicity in 2010 | Q17485680 |
| | Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission | Q24193716 |
| | Primaquine for reducing Plasmodium falciparum transmission | Q24200471 |
| | Spiroindolones, a potent compound class for the treatment of malaria | Q24606915 |
| | Climate change and the global malaria recession | Q24634284 |
| | Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether | Q24792020 |
| | Blocking malaria transmission to Anopheles mosquitoes using artemisinin derivatives and primaquine: a systematic review and meta-analysis | Q27014789 |
| | Identification of xanthurenic acid as the putative inducer of malaria development in the mosquito | Q28265888 |
| | Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate | Q28469316 |
| | Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity | Q28474141 |
| | The potential contribution of mass treatment to the control of Plasmodium falciparum malaria | Q28478260 |
| | Activity of clinically relevant antimalarial drugs on Plasmodium falciparum mature gametocytes in an ATP bioluminescence "transmission blocking" assay | Q28482292 |
| | High efficiency transfection of Plasmodium berghei facilitates novel selection procedures | Q30080002 |
| | Malaria vaccine research and development: the role of the WHO MALVAC committee | Q33611463 |
| | A research agenda for malaria eradication: vaccines | Q33818046 |
| | Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs | Q33898575 |
| | Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial | Q34038938 |
| | Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. | Q34331552 |
| | The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in South sumatra, Western indonesia: an open-label, randomized, controlled trial | Q34486508 |
| | Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria | Q34693880 |
| | A malaria gametocytocidal assay using oxidoreduction indicator, alamarBlue | Q34786064 |
| | A high-throughput screen targeting malaria transmission stages opens new avenues for drug development | Q34833899 |
| | Identification of MMV malaria box inhibitors of plasmodium falciparum early-stage gametocytes using a luciferase-based high-throughput assay | Q34995863 |
| | Lack of molecular correlates of Plasmodium vivax ookinete development | Q35131352 |
| | The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector | Q36086489 |
| | Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common | Q36538990 |
| | Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction | Q36662865 |
| | Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials | Q36800842 |
| | The importance of mosquito behavioural adaptations to malaria control in Africa. | Q36848444 |
| | Transmission-blocking interventions eliminate malaria from laboratory populations. | Q36906724 |
| | Nonrandomized controlled trial of artesunate plus sulfadoxine-pyrimethamine with or without primaquine for preventing posttreatment circulation of Plasmodium falciparum gametocytes | Q36969682 |
| | Male and female Plasmodium falciparum mature gametocytes show different responses to antimalarial drugs | Q36969808 |
| | Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria | Q37121012 |
| | Quantitative assessment of DNA replication to monitor microgametogenesis in Plasmodium berghei | Q37461276 |
| | Modeling within-host effects of drugs on Plasmodium falciparum transmission and prospects for malaria elimination | Q37509562 |
| | Estimates of the changing age-burden of Plasmodium falciparum malaria disease in sub-Saharan Africa | Q37581763 |
| | Inhibiting Plasmodium cytochrome bc1: a complex issue | Q37767046 |
| | Gametocytocidal and sporontocidal effects of primaquine upon two strains of Plasmodium falciparum | Q38896552 |
| | The effect of combinations of qinghaosu (artemisinin) with standard antimalarial drugs in the suppressive treatment of malaria in mice | Q38940696 |
| | Gametocytocidal and sporontocidal effects of primaquine and of sulfadiazine with pyrimethamine in a chloroquine-resistant strain of Plasmodium falciparum | Q41940698 |
| | Heterogeneity in patterns of malarial oocyst infections in the mosquito vector | Q43048579 |
| | Measuring the blockade of malaria transmission--an analysis of the Standard Membrane Feeding Assay | Q43571629 |
| | Species-specific differences in coumarin-induced hepatotoxicity as an example toxicogenomics-based approach to assessing risk of toxicity to humans | Q43732061 |
| | Gametocytocidal and sporontocidal activity of antimalarials against Plasmodium berghei ANKA in ICR Mice and Anopheles stephensi mosquitoes | Q44142648 |
| | Malaria: some considerations regarding parasite productivity | Q44142926 |
| | Estimate of Plasmodium falciparum sporozoite content of Anopheles stephensi used to challenge human volunteers | Q44147527 |
| | Detection and quantification of Plasmodium falciparum and P. vivax infections in Thai-Kampuchean Anopheles (Diptera: Culicidae) by enzyme-linked immunosorbent assay | Q44150842 |
| | Identification of Malaria-Infected Mosquitoes by a Two-Site Enzyme-Linked Immunosorbent Assay | Q44165454 |
| | The design and interpretation of laboratory assays measuring mosquito transmission of Plasmodium | Q44165761 |
| | A high-throughput assay for the identification of malarial transmission-blocking drugs and vaccines | Q44166008 |
| | Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum | Q44167789 |
| | Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial | Q44168825 |
| | The in vitro cultivation of P. falciparum ookinetes, and their enrichment on Nycodenz density gradients | Q44812816 |
| | A general chain binomial model for infectious diseases | Q44883279 |
| | A green fluorescent protein-based assay for determining gametocyte production in Plasmodium falciparum | Q47888425 |
| | A high-throughput assay for the identification of drugs against late-stage Plasmodium falciparum gametocytes | Q47991005 |
| | Efficacy of different primaquine-based antimalarial regimens against Plasmodium falciparum gametocytemia | Q47999867 |
| | Effects of artemisinin derivatives on malaria transmissibility | Q48027455 |
| | Molecular Imaging | Q57904047 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antimalarial | Q521616 |
| P304 | page(s) | 490-497 | |
| P577 | publication date | 2014-11-10 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Lead clinical and preclinical antimalarial drugs can significantly reduce sporozoite transmission to vertebrate populations | |
| P478 | volume | 59 | |